ATP-sensitive potassium
(KATP) channels are present in numerous
organs, including the heart, brain, and pancreas. Physiological opening
and closing of KATPs present in pancreatic β-cells, in response
to changes in the ATP/ADP concentration ratio, are correlated with
insulin release into the bloodstream. Sulfonylurea drugs, commonly
used in type 2 diabetes mellitus treatment, bind to the octamer KATP
channels composed of four pore-forming Kir6.2 and four SUR1 subunits
and increase the probability of insulin release. Azobenzene-based
derivatives of sulfonylureas, such as JB253 inspired by well-established
antidiabetic drug glimepiride, allow for control of this process by
light. The mechanism of that phenomenon was not known until now. In
this paper, we use molecular docking, molecular dynamics, and metadynamics
to reveal structural determinants explaining light-controlled insulin
release. We show that both
trans-
and
cis-
JB253 bind to the same SUR1 cavity as antidiabetic sulfonylurea glibenclamide
(GBM). Simulations indicate that, in contrast to
trans-
JB253, the
cis-
JB253 structure generated by blue
light absorption promotes open structures of SUR1, in close similarity
to the GBM effect. We postulate that in the open SUR1 structures,
the N-terminal tail from Kir6.2 protruding into the SUR1 pocket is
stabilized by flexible enough sulfonylureas. Therefore, the adjacent
Kir6.2 pore is more often closed, which in turn facilitates insulin
release. Thus, KATP conductance is regulated by peptide linkers between
its Kir6.2 and SUR1 subunits, a phenomenon present in other biological
signaling pathways. Our data explain the observed light-modulated
activity of photoactive sulfonylureas and widen a way to develop new
antidiabetic drugs having reduced adverse effects.